Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries
Haemophilia · 2024
DOI: 10.1111/hae.14968 ↗Kurz gefasst
Leserbrief in der Zeitschrift Haemophilia, 2024. Verfasst von Pier Mannuccio Mannucci und 1 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Hemophilia A. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
- Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
ORCID-Profile: Pier Mannuccio Mannucci
Zitieren
APA
Mannucci, P. M., & Hermans, C. (2024). Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries. Haemophilia. https://doi.org/10.1111/hae.14968
Vancouver
Mannucci PM, Hermans C. Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries. Haemophilia. 2024. doi:10.1111/hae.14968
BibTeX
@article{Mannucci2024,
author = {Mannucci, Pier Mannuccio and Hermans, Cedric},
title = {Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.14968}
}
EUVIMED